EU may expand Tresiba indication

Share this article:

The EU's Committee for Medicinal Products for Human Use is endorsing expanded indications for Novo Nordisk's Type 2 diabetes medications Tresiba and Victoza.

The company said in a statement that if the European Medicines Agency agrees, new labels will indicate that the long-acting basal insulin Tresiba can be prescribed in tandem with a GLP-1 like Victoza, and that Victoza can be prescribed along with a long-acting basal insulin.

The potential expansion comes soon after the FDA put Tresiba at arm's-length in February, when it told the drugmaker to run cardiovascular safety tests before it would consider an approval.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions